Futura Medical plc is a pharmaceutical group that develops innovative products for the consumer healthcare market.
The Company's shares are quoted on the AIM market of the London Stock Exchange.
Futura Medical is committed to developing products with the potential for a significant return on the costs of development.
We are developing a portfolio of products in sexual healthcare and pain relief management and are evaluating further therapeutic opportunities as potential additions to the growing pipeline. We have currently four main products in development for sexual health and pain relief. These are CSD500, FLD500, MED2002 and TPR100.
SSL International has global distribution rights for both our condom products CSD500 and FLD500 and in September signed a global development and licensing agreement for MED2002, our erectile dysfunction gel.
Commercial negotiations are continuing on a non-exclusive basis with GlaxoSmithKline for the negotiation of global distribution rights for TPR100, our topical pain relief product.
We are actively working on the next generation of product opportunities, including PET500, as well as evaluating the use of our proprietary delivery system DermaSys® in a range of other compounds.
